Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Faivre

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Bulletin Du Cancer|April 10, 2009
[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools]G Malouf, C Dreyer, N Guedj, et al.
British Journal of Cancer|November 26, 2014
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinomaC Dos Santos, A Tijeras-Raballand, M Serova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancerV Boige, E Raymond, S Faivre, et al.
British Journal of Cancer|October 27, 2011
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patientsG Bousquet, J Alexandre, C Le Tourneau, et al.
Investigational New Drugs|March 30, 2013
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumorsE Raymond, J Alexandre, S Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 1999
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experienceS Faivre, S Kalla, E Cvitkovic, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 28, 2001
Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathwaysS Rodrigues, Q D Nguyen, S Faivre, et al.
Journal of Neuroradiology = Journal De Neuroradiologie|October 17, 2006
Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary resultsF Bidault, S Faivre, V Kuoch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumorsK Vera, L Djafari, S Faivre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomasE Raymond, S Faivre, G Weiss, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Bulletin Du Cancer|April 10, 2009
[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools]G Malouf, C Dreyer, N Guedj, et al.
British Journal of Cancer|November 26, 2014
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinomaC Dos Santos, A Tijeras-Raballand, M Serova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancerV Boige, E Raymond, S Faivre, et al.
British Journal of Cancer|October 27, 2011
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patientsG Bousquet, J Alexandre, C Le Tourneau, et al.
Investigational New Drugs|March 30, 2013
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumorsE Raymond, J Alexandre, S Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 1999
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experienceS Faivre, S Kalla, E Cvitkovic, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 28, 2001
Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathwaysS Rodrigues, Q D Nguyen, S Faivre, et al.
Journal of Neuroradiology = Journal De Neuroradiologie|October 17, 2006
Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary resultsF Bidault, S Faivre, V Kuoch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumorsK Vera, L Djafari, S Faivre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomasE Raymond, S Faivre, G Weiss, et al.
Pageof 7